This bill amends the Controlled Substance, Drug, Device and Cosmetic Act, specifically focusing on the provisions related to drug overdose medication. It updates the definition of "opioid antagonist" to include not only naloxone hydrochloride but also nalmefene hydrochloride and other similarly acting drugs that are approved by the United States Food and Drug Administration for the emergency reversal of known or suspected opioid overdoses. The changes aim to enhance the availability of effective treatments for opioid overdoses by broadening the scope of recognized medications. The bill will take effect 60 days after its enactment, ensuring that the updated definitions and provisions are implemented promptly to address the ongoing opioid crisis.

Statutes/Laws affected:
Printer's No. 2835 (Jan 30, 2026): P.L.233, No.64